CancerDrs

Cervical Cancer clinical trials in Colorado

25 actively recruiting cervical cancer trials at 26 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth Highlands Ranch Hospital — Highlands Ranch, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Colorado:
  • Site 130 — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • AdventHealth Porter — Denver, Colorado
  • CommonSpirit Cancer Center Mercy — Durango, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Colorado:
  • Rocky Mountain Regional VA Medical Center — Aurora, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Colorado:
  • Avenzo Therapeutics Recruiting Site — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Colorado:
  • University of Colorado Denver Anschultz Medical Campus — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

SMP-3124LP in Adults With Advanced Solid Tumors

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …

Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor typ…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07503808
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participan…

Sponsor: Genentech, Inc.
NCT ID: NCT05581004
Sites in Colorado:
  • University Of Colorado — Aurora, Colorado
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • The Medical Center of Aurora — Aurora, Colorado
  • Rocky Mountain Regional VA Medical Center — Aurora, Colorado
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • Boulder Community Foothills Hospital — Boulder, Colorado
View on ClinicalTrials.gov →
NA Recruiting NIH

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Colorado:
  • Keefe Memorial Hospital — Cheyenne Wells, Colorado
  • Kaiser Permanente-Franklin — Denver, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
  • UCHealth Greeley Hospital — Greeley, Colorado
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Improving Care for Rural Patients With Solid Tumors

This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cerv…

Sponsor: University of Colorado, Denver
NCT ID: NCT04916990
Sites in Colorado:
  • University of Colorado Hospital — Aurora, Colorado
  • Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • SCL- St. Mary's Medical Center — Grand Junction, Colorado
View on ClinicalTrials.gov →
Recruiting Academic/Other

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cance…

Sponsor: University of Colorado, Denver
NCT ID: NCT05517811
Sites in Colorado:
  • University of Colorado Denver — Aurora, Colorado
View on ClinicalTrials.gov →
Recruiting Academic/Other

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURP…

Sponsor: University of Colorado, Denver
NCT ID: NCT00900419
Sites in Colorado:
  • University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27